RxSight Inc Dossier - Source-backed chat

RxSight Inc

RXSTNASDAQ

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)1.09

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $4.75Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $197.6M

Enterprise Value $184.2M

Shares Outstanding 41.6M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

RxSight, Inc. (RXST) is a commercial-stage medical technology company offering the first and only post-operatively adjustable intraocular lens (IOL) system. While the clinical superiority of its Light Adjustable Lens (LAL) technology is highly regarded, the company is navigating a transition phase characterized by a deliberate slowdown in Light Delivery Device (LDD) capital placements and elevated operating expenses. Near-term financial performance is pressured by negative earnings and high inventory costs flowing through the P&L, though gross margins remain strong due to a favorable product mix shifting toward high-margin LAL consumables. A Hold recommendation is warranted until capital placement trends stabilize and international expansion begins to contribute meaningfully to the top line.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$6.50

Mean target$8.43

High · most bullish analyst$11.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$7.0015%

Macroeconomic headwinds or competitive launches from major IOL players (e.g., Alcon, Johnson & Johnson) lead to a further contraction in premium cataract procedures. LDD placements stall completely, and LAL utilization declines as practices face staffing shortages or limit premium offerings. Elevated operating expenses lead to a faster-than-expected cash burn, necessitating a dilutive financing round.

Base CaseCentral scenario

$9.0060%

RxSight executes in line with its reiterated 2026 guidance, delivering full-year revenue between $120 million and $135 million. LDD placements remain modest as the company prioritizes same-store sales and utilization. Gross margins compress slightly to the guided 70% to 72% range as higher-cost 2025 inventory flows through, while operating expenses land at the high end of the $150 million to $160 million range due to ongoing commercial investments.

Bull CaseUpside scenario

$11.0025%

Accelerated adoption of the LAL+ line extension and successful customer re-engagement programs drive a rapid recovery in LDD placements. Same-store LAL utilization increases significantly as surgeons fully transition their premium cataract procedures to RxSight's platform. International regulatory approvals in Europe, Australia, and New Zealand translate into early commercial wins, leading to positive earnings surprise and operating leverage.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Clinical Superiority: The LAL is the only FDA-approved IOL that can be customized post-surgery, delivering unmatched visual acuity outcomes (91.2% within 0.50 diopters of target).
High Recurring Revenue Potential: Consumable LAL sales represent 88% of total revenue as of Q1 2026, driving high gross margins (76.1% in Q1 2026).
Strong Balance Sheet: With $217.9 million in cash and short-term investments and minimal debt, the company has a solid runway to fund its commercial initiatives.

Key Investment Risks

Capital Equipment Headwinds: LDD sales have declined significantly (only 20 units sold in Q1 2026), reflecting slower adoption and deliberate pacing.
Lack of Profitability: The company continues to generate net losses ($15.9 million in Q1 2026) with operating expenses expected at the high end of guidance.
Intense Competition: RxSight competes against massive, well-entrenched ophthalmic giants like Alcon and Bausch + Lomb who possess extensive distribution networks.

Thesis Invalidation Triggers

A sustained drop in quarterly LAL unit sales below 25,000 units, indicating a decline in surgeon utilization.
Failure to maintain gross margins above 70%, pointing to severe pricing pressure or manufacturing inefficiencies.
A significant delay in international commercialization timelines, pushing expected 2027 growth drivers further out.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.